Scott Mittelstadt

Title: Scott Mittelstadt: Innovator in Dopamine D3 Receptor Modulation

Introduction

Scott Mittelstadt is a notable inventor based in North Chicago, Illinois. He holds a patent that focuses on acylaminocycloalkyl compounds, which are significant for treating disorders that respond to the modulation of the dopamine D3 receptor. His work contributes to the advancement of therapeutic options in the medical field.

Latest Patents

Mittelstadt's patent, titled "Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor," presents novel compounds that possess valuable therapeutic properties. These compounds, particularly those described in the formula I, along with their salts and N-oxides, are designed to address diseases linked to dopamine D3 receptor modulation.

Career Highlights

Throughout his career, Scott Mittelstadt has worked with prominent companies in the pharmaceutical industry, including AbbVie Deutschland GmbH & Co. KG and AbbVie Inc. His experience in these organizations has allowed him to contribute significantly to the field of medicinal chemistry and drug development.

Collaborations

Mittelstadt has collaborated with esteemed colleagues such as Andreas Haupt and Jürgen Dinges. These partnerships have likely enhanced his research and development efforts, leading to innovative solutions in the treatment of various disorders.

Conclusion

Scott Mittelstadt's contributions to the field of pharmacology through his patent on acylaminocycloalkyl compounds highlight his role as an innovator in the treatment of dopamine-related disorders. His work continues to pave the way for advancements in therapeutic options.